[The use of ticlid in diabetic retinopathy].
A clinical trial has been conducted of antiaggregation effects of tiklid in 100 diabetes mellitus patients with preproliferative and proliferative retinopathy. Tiklid was found to improve blood rheology, to promote partial recovery of retinal function. As such effects contribute to prevention of progression of the proliferative alterations, tiklid can be recommended for treatment of preproliferative and proliferative retinopathy in patients with diabetes mellitus.
Rubtsova
A L
AL
Ametov
A S
AS
Strakhov
V V
VV
D000293:Adolescent; D000328:Adult; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D003930:Diabetic Retinopathy / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007328:Insulin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012160:Retina / Q000187:drug effects / Q000503:physiopathology; D013607:Tablets; D013988:Ticlopidine / Q000627:therapeutic use*
D007328:Insulin; D010975:Platelet Aggregation Inhibitors; D013607:Tablets; D013988:Ticlopidine
Primenenie tiklida pri diabeticheskoĭ retinopatii.